CytoCore e2 Collector Compliant for the CE Mark.

Cervical Cell Collection Device Qualified to Sell in Europe

CHICAGO -- CytoCore (OTCBB:CYCR.OB), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that it has completed the process of demonstrating conformity of the e2 Collector[TM] cervical cell collection device to the requirements of the Medical Device Directive for sales into the European Union.

"We are pleased to have accomplished this significant objective. Demonstrating conformity to the essential requirements of the Medical Device Directive and, as a consequence, being able to affix the 'CE Mark' to the product is THE major milestone for selling the Collector into the European Union," said CytoCore's president, Dick Domanik. "In addition, the CE Mark is becoming increasingly important for entry into other countries. We are in the process of formally registering the e2 Collector with the individual countries as designated by our distribution partners. We are now ready to finalize certain initial distribution arrangements covering several European countries."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening, therapeutic and delivery systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.